欧盟法规
C&L通报上下游产品
4-[(1R)-2-({6-[(2-{[(2,6-dichlorophenyl)methyl]oxy}ethyl)oxy]-hexyl}-amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol triphenylacetic acid (2R)-hydroxy-2-(2,2-dimethyl-4Η-1,3-benzodioxole-6-yl)-N-3-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexyl]-ethylamine 2-bromo-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethanone (1R)-2-[[6-[2-[(2,6-二氯苄基)氧基]乙氧基]己基]氨基]-1-(2,2-二甲基-4H-1,3-苯并二氧杂环己-6-基)乙醇置于盐酸体系中,用 水,异丙醇,丙酮 作为反应溶剂,80.0 °C,300.01 Kpa 条件下,反应 3.5H,反应生成 维兰特罗三苯乙酸盐
参考文献:维兰特罗三芬酯选择性及公斤级合成路线优化
标题:维兰特罗三芬酯选择性及公斤级合成路线优化
摘要:活性成分维兰特罗三芬那酯是一种治疗慢性阻塞性肺病(Copd) 的有效药物,其改进的生产工艺已得到开发,具有高产率和纯度.这个稳健的过程在公斤规模上得到了证明.采用刮膜分子蒸馏法纯化高温下易分解的中间体,收率提高10%~15%.同时对相应的杂质进行了详细的研究并得到了很好的解决.最终,通过极具竞争力的总共 6 个步骤,获得了纯的维兰特罗三芬酯,收率为 57.9%,并且结晶纯度大于 99.9%,手性纯度为 99.9%,且没有单一主要杂质 >0.1%.
DOI:10.1016/j.Tet.2023.133604
海关参考信息
- 2902600000-乙苯
2903919090-氯苯
2905121000-正丙醇
2905130000-正丁醇 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
✅ COA系统入驻 | 共享模式
主要参考文献
1: Albertson TE, Richards JR, Zeki AA. The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience. Ther Adv Respir Dis. 2016 Feb;10(1):43-56. doi: 10.1177/1753465815619136. Epub 2015 Dec 14. Review. doi: 10.2147/TCRM.S67491. eCollection 2015. Review.
4: Albertson TE, Harper R, Murin S, Sandrock C. Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol. Patient Prefer Adherence. 2015 Feb 2;9:235-42. doi: 10.2147/PPA.S71535. eCollection 2015. Review.
5: Relvar Ellipta for asthma. Drug Ther Bull. 2014 Aug;52(8):93-6. doi: 10.1136/dtb.2014.8.0273. Review. doi: 10.1331/JAPhA.2014.14527. doi: 10.2147/COPD.S47792. eCollection 2014. Review.
合成参考文献
参考文献:10.1021/jm100326d
摘要:Procopiou PA, Barrett VJ, Bevan NJ, Biggadike K, Box PC, Butchers PR, Coe DM, Conroy R, Emmons A, Ford AJ, Holmes DS, Horsley H, Kerr F, Li-Kwai-Cheung AM, Looker BE, Mann IS, McLay IM, Morrison VS, Mutch PJ, Smith CE, Tomlin P. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010 Jun 10;53(11):4522–30. doi: 10.1021/jm100326d.